Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association.

[1]  B. Nordestgaard,et al.  High lipoprotein(a) and high risk of mortality. , 2019, European heart journal.

[2]  B. Nordestgaard,et al.  Elevated Lipoprotein(a) and Risk of Ischemic Stroke. , 2019, Journal of the American College of Cardiology.

[3]  Daniel E Forman,et al.  2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. , 2019, Journal of the American College of Cardiology.

[4]  F. Kronenberg,et al.  Estimation of the Required Lipoprotein(a)-Lowering Therapeutic Effect Size for Reduction in Coronary Heart Disease Outcomes: A Mendelian Randomization Analysis. , 2019, JAMA cardiology.

[5]  M. Koschinsky,et al.  Lipoprotein(a) and Oxidized Phospholipids Promote Valve Calcification in Patients With Aortic Stenosis , 2019, Journal of the American College of Cardiology.

[6]  S. Yusuf,et al.  Lipoprotein(a) Levels and the Risk of Myocardial Infarction Among 7 Ethnic Groups , 2019, Circulation.

[7]  G. Watts,et al.  Value of Measuring Lipoprotein(a) During Cascade Testing for Familial Hypercholesterolemia. , 2019, Journal of the American College of Cardiology.

[8]  M. Boffa,et al.  Oxidized phospholipids as a unifying theory for lipoprotein(a) and cardiovascular disease , 2019, Nature Reviews Cardiology.

[9]  A. Keech,et al.  Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk: Insights From the FOURIER Trial , 2019, Circulation.

[10]  Odyssey Outcomes Investigators.  Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome , 2018 .

[11]  M. Koschinsky,et al.  JCL roundtable-Lipoprotein(a): The emerging risk factor. , 2018, Journal of clinical lipidology.

[12]  J. Ralphe,et al.  In pediatric familial hypercholesterolemia, lipoprotein(a) is more predictive than LDL-C for early onset of cardiovascular disease in family members. , 2018, Journal of clinical lipidology.

[13]  George Hripcsak,et al.  LPA Variants Are Associated With Residual Cardiovascular Risk in Patients Receiving Statins , 2018, Circulation.

[14]  W. Guan,et al.  Lp(a) [Lipoprotein(a)]-Related Risk of Heart Failure Is Evident in Whites but Not in Other Racial/Ethnic Groups: The Multi-Ethnic Study of Atherosclerosis , 2018, Arteriosclerosis, thrombosis, and vascular biology.

[15]  F. Kronenberg,et al.  Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials , 2018, The Lancet.

[16]  B. Nordestgaard,et al.  From genome-wide association studies to Mendelian randomization: novel opportunities for understanding cardiovascular disease causality, pathogenesis, prevention, and treatment. , 2018, Cardiovascular research.

[17]  N. Cook,et al.  Lipoprotein(a) and Cardiovascular Risk Prediction Among Women. , 2018, Journal of the American College of Cardiology.

[18]  James R. Staley,et al.  Association of LPA Variants With Risk of Coronary Disease and the Implications for Lipoprotein(a)-Lowering Therapies: A Mendelian Randomization Analysis , 2018, JAMA cardiology.

[19]  N. Wareham,et al.  Cardiovascular disease risk associated with elevated lipoprotein(a) attenuates at low low-density lipoprotein cholesterol levels in a primary prevention setting , 2018, European heart journal.

[20]  J. Noel-MacDonnell,et al.  Lipoprotein (a): Examination of Cardiovascular Risk in a Pediatric Referral Population , 2018, Pediatric Cardiology.

[21]  Deepak L. Bhatt,et al.  Lp(a) and Cardiovascular Outcomes: an Analysis from the ODYSSEY OUTCOMES Trial , 2018, Atherosclerosis Supplements.

[22]  D. Panagiotakos,et al.  High levels of lipoprotein (a) and premature acute coronary syndrome. , 2018, Atherosclerosis.

[23]  M. Landray,et al.  Impact of Apolipoprotein(a) Isoform Size on Lipoprotein(a) Lowering in the HPS2-THRIVE Study , 2018, Circulation. Genomic and precision medicine.

[24]  D. Rader,et al.  NHLBI Working Group Recommendations to Reduce Lipoprotein(a)-Mediated Risk of Cardiovascular Disease and Aortic Stenosis. , 2018, Journal of the American College of Cardiology.

[25]  M. Lathrop,et al.  Association of LPA Variants With Aortic Stenosis: A Large-Scale Study Using Diagnostic and Procedural Codes From Electronic Health Records , 2017, JAMA cardiology.

[26]  M. Elkind,et al.  Dyslipidemia in Children with Arterial Ischemic Stroke : Prevalence and Risk Factors 1 ( running title : Dyslipidemia in Children with AIS ) 2 3 , 2017 .

[27]  G. Watts,et al.  Depicting new pharmacological strategies for familial hypercholesterolaemia involving lipoprotein (a) , 2017, European heart journal.

[28]  G. Abecasis,et al.  Genome-wide analysis yields new loci associating with aortic valve stenosis , 2017, bioRxiv.

[29]  B. Nordestgaard,et al.  High Lipoprotein(a) and Low Risk of Major Bleeding in Brain and Airways in the General Population: a Mendelian Randomization Study. , 2017, Clinical chemistry.

[30]  B. Nordestgaard,et al.  Oxidized Phospholipids and Risk of Calcific Aortic Valve Disease: The Copenhagen General Population Study , 2017, Arteriosclerosis, thrombosis, and vascular biology.

[31]  D. Pennell,et al.  Apheresis as novel treatment for refractory angina with raised lipoprotein(a): a randomized controlled cross-over trial , 2017, European heart journal.

[32]  A. Keech,et al.  Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease , 2017, The New England journal of medicine.

[33]  G. Watts,et al.  Predicting Cardiovascular Events in Familial Hypercholesterolemia: The SAFEHEART Registry (Spanish Familial Hypercholesterolemia Cohort Study) , 2017, Circulation.

[34]  P. Grützmacher,et al.  The German Lipoprotein Apheresis Registry (GLAR) – almost 5 years on , 2017, Clinical Research in Cardiology Supplements.

[35]  S. Tsimikas.  A Test in Context: Lipoprotein(a): Diagnosis, Prognosis, Controversies, and Emerging Therapies. , 2017, Journal of the American College of Cardiology.

[36]  Jennifer G. Robinson,et al.  Effect of Alirocumab on Lipoprotein(a) Over ≥1.5 Years (from the Phase 3 ODYSSEY Program). , 2017, The American journal of cardiology.

[37]  G. Watts,et al.  Familial combined hyperlipidemia and hyperlipoprotein(a) as phenotypic mimics of familial hypercholesterolemia: Frequencies, associations and predictions. , 2016, Journal of clinical lipidology.

[38]  Ž. Reiner,et al.  Effect of extended-release niacin on plasma lipoprotein(a) levels: A systematic review and meta-analysis of randomized placebo-controlled trials. , 2016, Metabolism: clinical and experimental.

[39]  G. Francis,et al.  2016 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult. , 2016, The Canadian journal of cardiology.

[40]  B. Nordestgaard,et al.  Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology , 2016, Journal of Lipid Research.

[41]  A. Hoes,et al.  2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. , 2016, European heart journal.

[42]  F. Kronenberg,et al.  Lipoprotein Apheresis for Lipoprotein(a)-Associated Cardiovascular Disease: Prospective 5 Years of Follow-Up and Apolipoprotein(a) Characterization. , 2016, Arteriosclerosis, thrombosis, and vascular biology.

[43]  B. Nordestgaard,et al.  High lipoprotein(a) as a possible cause of clinical familial hypercholesterolaemia: a prospective cohort study. , 2016, The lancet. Diabetes & endocrinology.

[44]  S. Tsimikas,et al.  Lipoprotein(a) and oxidized phospholipids in calcific aortic valve stenosis , 2016, Current opinion in cardiology.

[45]  L. Berglund,et al.  Lipoprotein (a): impact by ethnicity and environmental and medical conditions , 2016, Journal of Lipid Research.

[46]  G. Lippi,et al.  Evidence-based assessment of lipoprotein(a) as a risk biomarker for cardiovascular diseases – Some answers and still many questions , 2016, Critical reviews in clinical laboratory sciences.

[47]  M. Boffa,et al.  Lipoprotein (a): truly a direct prothrombotic factor in cardiovascular disease? , 2016, Journal of Lipid Research.

[48]  S. Marcovina,et al.  Lipoprotein (a) measurements for clinical application , 2016, Journal of Lipid Research.

[49]  J. Cigarroa,et al.  Further Evolution of the ACC/AHA Clinical Practice Guideline Recommendation Classification System: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. , 2016, Journal of the American College of Cardiology.

[50]  B. Nordestgaard,et al.  Elevated Lipoprotein(a) Levels, LPA Risk Genotypes, and Increased Risk of Heart Failure in the General Population. , 2016, JACC. Heart failure.

[51]  J. Mckenney,et al.  National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 2. , 2015, Journal of clinical lipidology.

[52]  K. S. Lange,et al.  Lipoprotein (a) as a risk factor for ischemic stroke: a meta-analysis. , 2015, Atherosclerosis.

[53]  Y. Bossé,et al.  Oxidized Phospholipids, Lipoprotein(a), and Progression of Calci fi c Aortic Valve Stenosis , 2017 .

[54]  F. Kronenberg,et al.  Lipoprotein(a) levels are associated with aortic valve calcification in asymptomatic patients with familial hypercholesterolaemia , 2015, Journal of internal medicine.

[55]  J. Viikari,et al.  High lipoprotein(a) concentrations are associated with impaired endothelial function in children. , 2015, The Journal of pediatrics.

[56]  W. Guan,et al.  Race Is a Key Variable in Assigning Lipoprotein(a) Cutoff Values for Coronary Heart Disease Risk Assessment: The Multi-Ethnic Study of Atherosclerosis , 2015, Arteriosclerosis, thrombosis, and vascular biology.

[57]  J. Mckenney,et al.  National lipid association recommendations for patient-centered management of dyslipidemia: part 1--full report. , 2015, Journal of clinical lipidology.

[58]  L. Hemphill,et al.  Lipoprotein apheresis. , 2015, Cardiology clinics.

[59]  R. Califf,et al.  Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. , 2015, The New England journal of medicine.

[60]  Matti Pirinen,et al.  Pharmacogenetic meta-analysis of genome-wide association studies of LDL cholesterol response to statins , 2014, Nature Communications.

[61]  F. Kronenberg,et al.  Discrimination and net reclassification of cardiovascular risk with lipoprotein(a): prospective 15-year outcomes in the Bruneck Study. , 2014, Journal of the American College of Cardiology.

[62]  Sarah Parish,et al.  Effects of extended-release niacin with laropiprant in high-risk patients. , 2014, The New England journal of medicine.

[63]  J. Fleg,et al.  Safety profile of extended-release niacin in the AIM-HIGH trial. , 2014, The New England journal of medicine.

[64]  R. Giugliano,et al.  Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1,300 patients in 4 phase II trials. , 2014, Journal of the American College of Cardiology.

[65]  S. Solomon,et al.  Lipoprotein(a) for risk assessment in patients with established coronary artery disease. , 2014, Journal of the American College of Cardiology.

[66]  E. Steinhagen-Thiessen,et al.  Does regular lipid apheresis in patients with isolated elevated lipoprotein(a) levels reduce the incidence of cardiovascular events? , 2014, Artificial organs.

[67]  M. Elkind,et al.  Review of Lipid and Lipoprotein(a) Abnormalities in Childhood Arterial Ischemic Stroke , 2014, International journal of stroke : official journal of the International Stroke Society.

[68]  A. Khera,et al.  Lipoprotein(a) Concentrations, Rosuvastatin Therapy, and Residual Vascular Risk: An Analysis From the JUPITER Trial (Justification for the Use of Statins in Prevention An Intervention Trial Evaluating Rosuvastatin) , 2013, Circulation.

[69]  M. Sandhu,et al.  Lipoprotein(a) levels, genotype and incident aortic stenosis: a prospective Mendelian randomization study and replication in a case-control cohort , 2013 .

[70]  B. Nordestgaard,et al.  Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population. , 2013, Journal of the American College of Cardiology.

[71]  H. White,et al.  Plasma Lipoprotein(a) Concentration Predicts Future Coronary and Cardiovascular Events in Patients With Stable Coronary Heart Disease , 2013, Arteriosclerosis, thrombosis, and vascular biology.

[72]  Jennifer G. Robinson,et al.  Relationship of apolipoproteins A-1 and B, and lipoprotein(a) to cardiovascular outcomes: the AIM-HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglyceride and Impact on Global Health Outcomes). , 2013, Journal of the American College of Cardiology.

[73]  S. Marcovina,et al.  Elevated lipoprotein (a), small apolipoprotein (a), and the risk of arterial ischemic stroke in North American children , 2013, Haematologica.

[74]  Kathleen F. Kerr,et al.  Genetic associations with valvular calcification and aortic stenosis. , 2013, The New England journal of medicine.

[75]  K. Kario,et al.  Inverse association between serum lipoprotein(a) and cerebral hemorrhage in the Japanese population. , 2013, Thrombosis research.

[76]  F. Kronenberg,et al.  Lipoprotein(a): resurrected by genetics , 2013, Journal of internal medicine.

[77]  J. Danesh,et al.  Large-scale association analysis identifies new risk loci for coronary artery disease , 2013 .

[78]  J. Witztum,et al.  Acute impact of apheresis on oxidized phospholipids in patients with familial hypercholesterolemia1 , 2012, Journal of Lipid Research.

[79]  Anne Tybjærg-Hansen,et al.  Genetic Evidence That Lipoprotein(a) Associates With Atherosclerotic Stenosis Rather Than Venous Thrombosis , 2012, Arteriosclerosis, thrombosis, and vascular biology.

[80]  M. Caulfield,et al.  Genome-wide association study of genetic determinants of LDL-c response to atorvastatin therapy: importance of Lp(a) [S] , 2012, Journal of Lipid Research.

[81]  Eric Boerwinkle,et al.  Associations Between Lipoprotein(a) Levels and Cardiovascular Outcomes in Black and White Subjects: The Atherosclerosis Risk in Communities (ARIC) Study , 2011, Circulation.

[82]  M. Okubo,et al.  Lipoprotein(a)-cholesterol: a significant component of serum cholesterol. , 2011, Clinica chimica acta; international journal of clinical chemistry.

[83]  Alan S. Brown,et al.  Clinical utility of inflammatory markers and advanced lipoprotein testing: advice from an expert panel of lipid specialists. , 2011, Journal of clinical lipidology.

[84]  Thomas W. Mühleisen,et al.  Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease , 2011, Nature Genetics.

[85]  R. Collins,et al.  Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials , 2010, The Lancet.

[86]  J. Borén,et al.  Lipoprotein(a) as a cardiovascular risk factor: current status , 2010, European heart journal.

[87]  J. Danesh,et al.  Apolipoprotein(a) isoforms and the risk of vascular disease: systematic review of 40 studies involving 58,000 participants. , 2010, Journal of the American College of Cardiology.

[88]  F. Kirkham,et al.  Impact of Thrombophilia on Risk of Arterial Ischemic Stroke or Cerebral Sinovenous Thrombosis in Neonates and Children: A Systematic Review and Meta-Analysis of Observational Studies , 2010, Circulation.

[89]  R. Collins,et al.  Genetic variants associated with Lp(a) lipoprotein level and coronary disease. , 2009, The New England journal of medicine.

[90]  Stephen Kaptoge,et al.  Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. , 2009, JAMA.

[91]  Børge G Nordestgaard,et al.  Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. , 2009, JAMA.

[92]  Benjamin J. Wright,et al.  Genome-wide haplotype association study identifies the SLC22A3-LPAL2-LPA gene cluster as a risk locus for coronary artery disease , 2009, Nature Genetics.

[93]  G. Utermann,et al.  Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events , 2009, Nature Clinical Practice Cardiovascular Medicine.

[94]  P. Ridker,et al.  Lipoprotein(a), hormone replacement therapy, and risk of future cardiovascular events. , 2008, Journal of the American College of Cardiology.

[95]  B. Nordestgaard,et al.  Extreme Lipoprotein(a) Levels and Risk of Myocardial Infarction in the General Population: The Copenhagen City Heart Study , 2008 .

[96]  V. Thijs,et al.  Lipoprotein (a) and Stroke: A Meta-Analysis of Observational Studies , 2007, Stroke.

[97]  Sarah Lewis,et al.  Genetic epidemiology and public health: hope, hype, and future prospects , 2005, The Lancet.

[98]  M. Koschinsky,et al.  Report of the National Heart, Lung, and Blood Institute Workshop on Lipoprotein(a) and Cardiovascular Disease: recent advances and future directions. , 2003, Clinical chemistry.

[99]  S. Ebrahim,et al.  'Mendelian randomization': can genetic epidemiology contribute to understanding environmental determinants of disease? , 2003, International journal of epidemiology.

[100]  N. Rifai,et al.  Use of a reference material proposed by the International Federation of Clinical Chemistry and Laboratory Medicine to evaluate analytical methods for the determination of plasma lipoprotein(a). , 2000, Clinical chemistry.

[101]  J. Danesh,et al.  Lipoprotein(a) and Coronary Heart Disease: Meta-Analysis of Prospective Studies , 2000, Circulation.

[102]  E. Vittinghoff,et al.  Estrogen and progestin, lipoprotein(a), and the risk of recurrent coronary heart disease events after menopause. , 2000, JAMA.

[103]  A. Ganser,et al.  Increased lipoprotein (a) levels as an independent risk factor for venous thromboembolism. , 2000, Blood.

[104]  A. von Eckardstein,et al.  Lipoprotein (a) and genetic polymorphisms of clotting factor V, prothrombin, and methylenetetrahydrofolate reductase are risk factors of spontaneous ischemic stroke in childhood. , 1999, Blood.

[105]  J. Haddow,et al.  Lipoprotein(a) as a risk factor for ischemic heart disease: metaanalysis of prospective studies. , 1998, Clinical chemistry.

[106]  S Hulley,et al.  Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. , 1998, JAMA.

[107]  G. Dagenais,et al.  Is lipoprotein(a) an independent risk factor for ischemic heart disease in men? The Quebec Cardiovascular Study. , 1998, Journal of the American College of Cardiology.

[108]  W. Min,et al.  Relation between lipoprotein(a) concentrations in patients with acute-phase response and risk analysis for coronary heart disease. , 1997, Clinical chemistry.

[109]  M. Koschinsky,et al.  Effect of the number of apolipoprotein(a) kringle 4 domains on immunochemical measurements of lipoprotein(a). , 1995, Clinical chemistry.

[110]  Richard H. Myers,et al.  Familial Lipoprotein Disorders in Patients With Premature Coronary Artery Disease , 1992, Circulation.

[111]  A. del Río.  [Lipoprotein (a)]. , 1991, Medicina clinica.

[112]  E. Boerwinkle,et al.  Defects in the low density lipoprotein receptor gene affect lipoprotein (a) levels: multiplicative interaction of two gene loci associated with premature atherosclerosis. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[113]  G. Beck,et al.  Serum Lp(a) level as a predictor of vein graft stenosis after coronary artery bypass surgery in patients. , 1988, Circulation.

[114]  J. Goldstein,et al.  Teaching old dogmas new tricks , 1987, Nature.